A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients with Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  • Si Lun Tam, Con (Primary Chief Investigator (PCI))
  • Malherbe, Maturos (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date17/03/23 → 16/03/25

Keywords

  • Clinical trial
  • Marginal Zone Lymphoma
  • BGB-3111